• Executing against strategy for long-term growth and value creation
• Strong commercial performance enables continued investment for future growth
• Significant expansion of global manufacturing operations, including RLS acquisition

Telix Pharmaceuticals reported a strong H1 2025, with group revenue up 63% year-over-year to $390.4 million. This was driven by continued growth in Illuccix sales, as well as revenue contribution from the recently acquired RLS Radiopharmacies business. Gross margins remained stable at 64% for the Precision Medicine segment. The company continued to invest in its pipeline, with R&D expenditure up 47% year-over-year to $81.6 million. Key pipeline highlights include the completion of target enrollment for the ProstACT Global Phase 3 trial, approval to commence the IPAX-BrIGHT pivotal trial in glioblastoma, and the opening of enrollment for the BiPASS Phase 3 study for prostate cancer diagnosis. Telix also made strategic acquisitions to expand its next-generation therapeutics platform and pipeline. The integration of RLS is on track, significantly increasing Telix's U.S. footprint and manufacturing and distribution capabilities. The company maintained positive operating cash flow of $17.7 million and ended the period with a cash balance of $207.2 million, which will support its continued investment in growth initiatives.

Telix reaffirmed its FY 2025 revenue guidance of $770 million to $800 million. R&D expenditure is expected to increase 20% to 25% compared to FY 2024.